VTYX - Ventyx Biosciences

-

$undefined

N/A

(N/A)

Ventyx Biosciences NasdaqGS:VTYX Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Location: 12790 El Camino Real, Suite 250, San Diego, CA, 92130, United States | Website: https://ventyxbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-89.46M

Cash

228.8M

Avg Qtr Burn

-27.24M

Short % of Float

11.09%

Insider Ownership

4.14%

Institutional Own.

68.47%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

VTX3232 Details
Obesity and cardiometabolic risk factors

Phase 2

Data readout

Phase 2

Update

Phase 2

Update

VTX3232 Details
Parkinson's disease

Big Mover™

Susp. Mover™

Phase 2a

Data readout

VTX958 (TYK2 inhibitor) Details
Psoriatic arthritis, Psoriasis

Failed

Discontinued